Cosmo Pharmaceuticals N.V. Overview
Pro stress-test →Cosmo Pharmaceuticals focuses on the development and commercialization of products for gastroenterology, dermatology, and healthtech worldwide. The company achieved full-year 2024 revenue of €265.7 million, marking a 186% increase compared to 2023. With year-end cash and short-term investments of €170.4 million and zero debt, Cosmo maintains a robust balance sheet.
Strategic Profile
Pro stress-test →The company is undergoing a transformation into a focused, innovation-driven healthcare leader with strategic growth priorities across MedTech AI, dermatology, gastroenterology, and CDMO. For commercialization and distribution, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma.
Competitive Landscape
Pro stress-test →Cosmo has development and distribution agreements with major players including Bausch Health, Ferring, Medtronic, RedHill Biopharma, Sun Pharmaceutical, and others. The company competes in specialized segments of gastroenterology and dermatology with differentiated AI-enabled endoscopy technology. Strategic partnerships position it as a development and commercialization partner rather than a pure competitor.
Industry Context
Cosmo Pharmaceuticals N.V. operates in Specialty Pharmaceuticals & Medical Devices / Healthtech.
Key facts
Founded: 1997 · Headquarters: Dublin, Ireland · Employees: 330 · Revenue: €265.7M (2024)